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Abstract
Background Within the Australian public hospital setting, no studies have previously reported total hospital utilisation and 
costs (pre/postoperatively) and costed patient-level pathways for primary bariatric surgery and surgical sequelae (including 
secondary surgery) informed by Australia’s Independent Hospital Pricing Authority’s activity-based funding (ABF) model.
Objective We aimed to provide our Tasmanian state government partner with information regarding key evidence gaps about the 
resource use and costs of bariatric surgery (including pre- and postoperatively, types of surgery and comorbidities), the costs of 
surgical sequelae and policy direction regarding the types of bariatric surgery offered within the Tasmanian public hospital system.
Methods Hospital inpatient length of stay (days), episodes of care (number) and aggregated cost data were extracted for 
people who were waiting for and subsequently received bariatric surgery (for the fiscal years 2007–2008 to 2015–2016) from 
administrative sources routinely collected, clinically coded/costed according to ABF. Aggregated ABF costs were expressed 
in 2016–2017 Australian dollars ($A). Sensitivity (cost outliers) and subgroup analyses were conducted.
Results A total of 105 patients entered the study. Total costs (pre/postoperative over 8 years) for all inpatient episodes of care 
(n = 779 episodes of care) were $A6,018,349. When the ten cost outliers were omitted from the total cost, this cost reduced 
to $A4,749,265. Mean costs for primary laparoscopic adjustable gastric band (LAGB) and sleeve gastrectomy (SG) bariatric 
surgery were $A14,622 and $A15,014, respectively. The average cost/episode of care for people with diabetes decreased in 
the first year postoperatively, from $A7258 to $A5830/episode of care. In total, 27 LAGB patients (30%) required surgery 
due to surgical sequelae (including revisional/secondary surgery; n = 58 episodes of care) and 56% of these episodes of care 
were secondary LAGB device related (mostly port/reservoir related), with a mean cost of $A6267.
Conclusions Taking into account our small SG sample size and the short time horizon for investigating surgical sequalae 
for SG, costs may be mitigated in the Tasmanian public hospital system by substituting LAGB with SG when clinically 
appropriate due to costs associated with the LAGB device for some patients. At 3 years postoperatively versus preoperatively, 
episodes of care and costs reduced substantially, particularly for people with diabetes/cardiovascular disease. We recommend 
that a larger confirmatory study of bariatric surgery including LAGB and SG be undertaken of disaggregated ABF costs in 
the Tasmanian public hospital system.
 * Andrew J. Palmer 
 Andrew.Palmer@utas.edu.au
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1 Introduction
1.1  Obesity and Bariatric Surgery: The Australian 
Context
The obesity epidemic is a complex public health, economic 
and strategic policy problem [1–4].
The most recent estimate in the published literature of the 
total annual direct cost of overweight and obesity in Aus-
tralia in 2005 was 21 billion Australian dollars ($A), and this 
estimate was substantially higher than previous estimates 
[5]. An international study has established that costs rise 
rapidly in the range of severe obesity [6].
In Australia, over 60% of adults are overweight or obese 
and, in line with global trends, the rate of severe obesity 
(body mass index (BMI) ≥ 35 kg/m2) is increasing more 
rapidly than overweight and obesity (overweight BMI 
25–29.9 kg/m2; obesity BMI 30–34.9 kg/m2) [7–9]. Given 
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Key Points for Decision Makers 
This is the first Australian study to investigate patient-
level journeys of resource use and costs for publicly 
waitlisted patients before and after bariatric surgery over 
a lengthy time horizon.
Public hospital inpatient costs of providing bariatric 
surgery decrease from year 3 after surgery, with costs 
peaking at year 2.
Laparoscopic adjustable gastric band appliance-related 
costs are prevalent.
adjusted to the individual needs of the patient; however, the 
procedure has longer-term potential risks of band slippage, 
erosion and foreign body infection [13]. Some studies have 
called for a reconsideration of adjustable gastric band sur-
gery (compared with other bariatric procedures such as SG), 
particularly for Medicare beneficiaries in the USA [14–16].
The Australian healthcare system presents a complex 
and fragmented set of arrangements between the public 
(two tiers of government) and private sectors [17]. Austral-
ia’s Commonwealth government holds the major revenue-
raising power. Australian state governments operate public 
hospitals, which account for about two-thirds of all hospi-
talisations and provide emergency department visits with-
out charge. Australia’s National Health Reform Agreement 
established the new basis for the Commonwealth’s contribu-
tion to public hospital funding based on a hospital’s casemix 
and defined as activity-based funding (ABF) [18, 19]. Con-
strained public sector budgets contribute to the inability of 
the Australian public health system to address the problems 
of severe obesity increasing more rapidly than obesity [1, 
20]. This problem is reflected internationally [17, 21–23].
The Australian Institute for Health and Welfare (AIHW) 
report regarding weight loss surgery in Australia reported 
that, in 2014–2015, more than 22,700 weight loss surgery 
separations were conducted in Australia, most of which 
involved a primary procedure (79.4%) [7]. The majority of 
these bariatric surgery separations (88.0%; 20,000 separa-
tions) occurred in private hospitals, and the most common 
procedure for both public and private hospitals in Australia 
was laparoscopic SG (52.5%) [7].
A recent Australian study determined that the potential 
demand for publicly and privately funded bariatric surgery in 
Australia was 882,441 adults aged 18–65 years [24]. Impor-
tantly, 45.8% of these potential bariatric surgery candidates 
had no private health insurance [24]. Our recent qualitative 
health economics study found that many of the people who 
partially or fully self-funded their bariatric surgery experi-
enced economic burden to do so [25]. This qualitative study 
also found that some people were accessing their superan-
nuation to fund their surgery because they either had no 
private health insurance or they had to pay the concomitant 
health insurance gap [25].
The AIHW report regarding weight loss surgery in Aus-
tralia used Medicare data to analyse the costs of bariatric 
surgery. The report suggested further research could report 
on ‘typical patient journeys’, incorporating a broad range of 
direct medical costs (rather than just analysing Medicare-
linked data). The report stated that the ability to track and 
analyse patient journeys from primary through to surgical 
sequelae (including secondary surgery) would greatly assist 
in understanding the broader relationships between primary 
surgical procedures and subsequent adjustments and revi-
sions and their associated costs [7]. Notably this AIHW 
this increasing trend of severe obesity, recent clinical litera-
ture also describes a fourth class of obesity, known as ‘super-
obesity’ defined as a BMI of ≥ 50 kg/m2 [10]. The Australian 
National Health and Medical Research Council (NHMRC) 
clinical guidelines regarding the management of overweight 
and obesity recommend bariatric (obesity, weight loss, met-
abolic [11]) surgery as a treatment option for severe obe-
sity where lifestyle modifications have been ineffective in 
reducing the person’s weight [12]. The NHMRC guidelines 
state that, for adults with BMI > 40 kg/m2 or adults with 
BMI > 35 kg/m2 and comorbidities that may improve with 
weight loss, bariatric surgery may be considered, taking into 
account the individual situation. The guidelines also state 
that bariatric surgery may also be a consideration for people 
with a BMI > 30 kg/m2 who have poorly controlled type 2 
diabetes mellitus and are at increased cardiovascular risk, 
taking into account the individual situation. The Australian 
guidelines also state that bariatric surgery is not generally an 
immediate consideration unless other interventions have not 
been successful, or other interventions are contraindicated, 
or a person’s BMI is > 50 kg/m2.
Bariatric surgical procedures involve gastric restriction 
to augment early satiety and limit meal portions, or intesti-
nal diversion designed to reduce caloric absorption. Some 
bariatric procedures contain elements of restriction and 
diversion. Sleeve gastrectomy (SG) is the most prevalent 
procedure in Australia and has been described as being less 
technically demanding than the gastric bypass or biliopan-
creatic diversion with duodenal switch, has minimal morbid-
ity, involves no implanted device and is without marginal 
ulcers, dumping syndrome, internal hernias, or nutritional 
deficiencies [13]. Complications are mainly staple line leaks 
and strictures, but the leak rate has decreased with improved 
surgical techniques [13].
The goal of the adjustable gastric band bariatric surgi-
cal procedure [including the laparoscopic adjustable gastric 
band (LAGB)] was to develop a gastric band that could be 
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report only provided aggregate figures for the number of 
bariatric surgery separations for some Australian jurisdic-
tions, including Tasmania, suggesting a key evidence gap 
[7].
1.2  Previously Published Reviews
Our comprehensive systematic review of the health eco-
nomic evaluations of bariatric surgery found that bariatric 
surgery is potentially cost effective or even cost saving for 
severely obese patients (BMI ≥ 35 kg/m2) with concomi-
tant diabetes mellitus [1]. However, the review also found 
that costs due to complications and reoperations of bariatric 
surgery were only incorporated in one-third of the included 
studies [1]. Additionally, when these costs were included, 
the estimates of the costs of complications or reoperations 
were conservative or low probabilities of these events were 
assumed [1]. Another recent systematic review regarding 
reoperations after secondary bariatric surgery found that, 
despite being poorly reported, risks of reoperations and 
long-term complications and tertiary bariatric surgery are 
higher than the usually reported risks of short-term com-
plications [26]. The most recently published Australian 
cost–utility study of bariatric surgery adopted rates of com-
plications and reoperations from the literature, and the base 
case for the cost–utility study assumed a severely obese 
female cohort aged 30 years with no comorbidity at the time 
of the operation [27].
1.3  Objectives of this Study
An Australian NHMRC partnership project between the 
Tasmanian state government and the University of Tasma-
nia was developed, in part to investigate and identify direct 
medical costs for a retrospective cohort of bariatric surgery 
patients in Tasmania, based on the Australian Independent 
Hospital Pricing Authority’s ABF model.
Our state government project partner does not know the 
hospital utilisation and costs for people with severe obesity 
(mostly with concomitant comorbidity) who receive bari-
atric surgery in the Tasmanian public hospital system. Nor 
does our project partner know the relative costs of the two 
types of bariatric surgery offered in the Tasmanian public 
hospital system. Therefore, we aimed to estimate the health 
service resource use and direct costs for (1) patients waiting 
for bariatric surgery, (2) the index of surgery, and (3) up 
to 3 years post-surgery. We particularly aimed to investi-
gate health service use and costs over a longer timeframe 
and to track individual patient journeys, including surgical 
sequalae.
2  Methods
2.1  Study Design
2.1.1  Validated Guidelines
This study was conducted in accordance with validated 
guidelines. These included the Consolidated Health Eco-
nomic Evaluation Standards used to inform the quality of 
our study [28], the Independent Hospital Pricing Author-
ity Patient Costing Standards version 3.1, the Tasmanian 
Department of Health and Human Services (DHHS; now 
Department of Health [DoH]) Patient-Level Costing Policy 
and Manual (October 2016) [19] used to inform the defi-
nitions of episodes of care and costing of those episodes 
under ABF and the STROBE (Strengthening the Report-
ing of Observational Studies in Epidemiology) statement 
that informed the flow of patients into the study [29]. We 
also reported in accordance with the ISPOR (International 
Society for Pharmacoeconomics and Outcomes Research) 
Real-World Data Taskforce Report [30], which states that 
real-world data are essential for sound coverage and reim-
bursement decisions: Context matters greatly in determining 
the value of a particular type of intervention in any circum-
stance [30].
2.1.2  Study Setting and Perspective
This retrospective health economics study was part of a 
much broader mixed-methods partnership project between 
the Tasmanian State Government and the University of Tas-
mania. The partnership adopted the economic concepts of 
heterogeneity of human capital [31], division of labour [32] 
and comparative advantage [33] to drive a clinical costing 
research team between government and university research-
ers regarding bariatric surgery in the Tasmanian public hos-
pital system. The team comprised state government officials 
who were experts in the department’s administrative data-
bases, clinical coding and costing (under the auspices of the 
Australian Independent Hospital Pricing Authority’s ABF 
model that informed the costs extracted for analyses), data-
base construction and raw cost data extraction; university 
researchers expert in clinical research, health economics and 
epidemiology; and a state government official who was a 
health economist, policy leader and decision maker within 
the department.
The costing was performed primarily from the Tasmanian 
Government’s perspective and, to a lesser extent, the Com-
monwealth Government’s perspective (under the National 
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Health Reform Agreement [18]). Relevant ethics approv-
als were obtained from the University of Tasmania’s Health 
and Medical Human Research Ethics Committee (approval 
number H0013845).
2.1.3  Study Population
From the patients who were enrolled on the Tasmanian 
public hospital waiting list for bariatric surgery between 1 
January 2008 and 31 December 2013 (and in line with our 
NHMRC partnership project and ethics approvals), the study 
population was defined as all patients who had received pri-
mary bariatric surgery in a Tasmanian public hospital (i.e. 
excluding patients contracted out into the private hospital 
sector for their bariatric surgery and patients treated else-
where privately using their own funds) and subsequently 
ABF costed for the primary procedure for the fiscal years 
2007–2008 to 2015–2016.
Patients who were then identified from the waiting list 
(1 January 2008 to 31 December 2013) as having received 
primary bariatric surgery in the Tasmanian public hospital 
system over this time horizon were then classified by surgery 
type: primary LAGB and primary SG. Importantly, these 
were the only forms of bariatric surgery performed in the 
public hospital system in Tasmania during this interval.
2.1.4  Activity‑Based Funding Model and the Extraction 
of Hospital Resource Use and Cost Data
A bottom-up costing methodology (in relation to the DoH 
predefined ABF cost buckets) for resource use and costing 
was used [34]. Within the ABF model, the DoH focused on 
costs at the patient level. The DoH states that a consistent 
approach to identifying how individual patient costs are built 
up can help organisations understand where variations arise 
within a patient pathway, for example, in theatres, wards or 
diagnostics [34]. The DoH’s development of patient-level 
costs builds costs from the bottom up, identifying where pos-
sible the resources used in treating individual patients—for 
example, prosthetic devices (such as an LAGB appliance), 
the intensity of nursing resources and indirect or overhead 
costs such as the costs of the payroll or finance team through 
appropriate allocation and apportionment methods [34].
More specifically, the DoH costing methodology for all 
patients admitted within the acute care system [34] adheres 
to six steps for ABF patient-level costing [19]:
1. ‘Define the patient care to be costed’—the first step is 
to identify the elements of patient care that need to be 
costed, for example operating theatre time, ward time, 
pharmaceuticals, theatre appliances (such as an adjust-
able gastric band). Figure 1 provides an outline of the 
DoH process to identify the patient care to be costed.
2. ‘Identify the activities’—to accurately assign costs to a 
defined element of patient care, the activities associated 
with delivering that care need to be accurately identified.
3. ‘Identify the relevant costs’—once the element of patient 
care to be costed has been defined, and associated activi-
ties and resources identified, the next step is to deter-
mine the relevant costs incurred in delivering the patient 
care.
4. ‘Classify costs’—after identifying costs for an element 
of patient care, the next step is to analyse and classify 
these costs. Under ABF, the Independent Hospital Pric-
ing Authority’s costing standards classify costs based 
on direct and overhead costs and fixed, semi-fixed and 
variable costs.
5. ‘Assign costs’—once the resource costs and activities 
underpinning the element of patient care to be costed 
have been fully analysed and understood, the next step is 
to assign the resource costs to the respective elements of 
patient care (costs can be attributed using the following 
methodologies: actual use, weighted costs, apportion-
ment based on relevant statistics such as floor area).
6. ‘Validate the outputs’—basis checks are undertaken to 
ensure the costing is accurate [34].
This study investigated the aggregated ABF costs that 
were generated from this costing method.
An episode of care is defined by the Australian Independ-
ent Hospital Pricing Authority as “A phase of treatment from 
admission to separation. An admission may be ‘statistical’ 
in that the patient changed from one type of admitted patient 
category to another (between any two of acute, rehabilita-
tion, palliation or non-acute) without being separated from 
the hospital. It follows that there must be a ‘statistical sepa-
ration’ before every statistical admission” [19]. Our study 
population’s primary bariatric surgery inpatient hospital 
admissions and all their preoperative and postoperative inpa-
tient hospital admissions (for the predefined time horizon 
of 2007–2008 to 2015–2016) were extracted to generate a 
unique episode of care number that was costed according to 
ABF [19, 35].
Table 1 (supported by Appendix 1A and B) provides 
examples of International Statistical Classification of Dis-
eases and Related Health Problems, Tenth Revision, Clinical 
Modification (ICD-10-CM), Australian Refined Diagnostic 
Related Group (AR-DRG) and procedure codes of interest 
for the primary LAGB and SG surgery [36, 37].
Patient sociodemographic (age, sex, smoking history and 
occupational status), clinical [BMI and comorbidity (diabe-
tes mellitus, cardiovascular disease)], resource use (length 
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of stay, in days) and cost data were extracted from the DoH’s 
Patient Management System and Clinical Cost databases. 
These variables and outcomes of interest are described in 
detail in Sect. 2.2.
2.2  Data Analyses: Key Variables and Outcomes 
of Interest
Patients’ sociodemographic and clinical characteristics and 
resource use and cost data were described as summary sta-
tistics of mean ± standard deviation (SD) and median [inter-
quartile range (IQR)] for continuous variables and frequen-
cies for categorical variables. It is noted that median and 
IQR were reported for cost data that are generally skewed.
Sociodemographic and clinical variables and their out-
comes of interest included age (at primary bariatric sur-
gery), sex, history of smoking (yes, no) and occupational 
status (employed, home duties, retired, pensioner, student or 
unemployed), BMI [before primary bariatric surgery BMI 
was calculated as weight (kg)/height  (m2)] and comorbidi-
ties (including documented history of diabetes mellitus and 
cardiovascular disease).
Key outcomes estimated from the patient-level resource 
utilisation and aggregated cost data were (1) the length of 
stay expressed in days (to ascertain the resource utilisation 
within the acute hospital setting) and direct medical costs 
of the inpatient episodes of care for primary bariatric sur-
gery in Tasmanian public hospitals for the predefined study 
population; (2) the number and aggregated costs of all inpa-
tient episodes of care before and after primary bariatric sur-
gery for the predefined study population from 2007–2008 
Fig. 1  The Tasmanian Depart-
ment of Health and Human 
Services patient-level cost-
ing process mapping. Source: 
Tasmanian Department of 
Health and Human Services 
Patient-Level Costing Guidance 
Manual (October 2016). IHPA 
Independent Hospital Pricing 
Authority, NHCDC National 
Hospital Cost Data Collection
Table 1  Examples of International Classification of Diseases, Tenth 
Revision, Clinical Modification, Australian Refined Diagnostic 
Related Group codes and procedure codes of interest for primary bar-
iatric surgery
AR-DRG Australian Refined Diagnostic-Related Group, ICD-10-CM 







 E10 Type 1 diabetes mellitus
 E11 Type 2 diabetes mellitus
AR-DRG codes
 G02A Major small and large bowel proce-
dures, major complexity
 G02B Major small and large bowel proce-
dures, intermediate complexity
 G05C Minor small and large bowel procedures
 K04A Major procedures for obesity
 K04B Major procedures for obesity
 K04Z Major procedures for obesity
 K12Z Other bariatric procedures
 K60 Diabetes
 K60A Diabetes minor complexity
Procedure codes
 30511-02 Laparoscopic adjustable gastric banding
 30511-04 Adjustable gastric banding
 30511-09 Laparoscopic sleeve gastrectomy
 30511-10 Sleeve gastrectomy
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to 2015–2016 (also expressed as mean cost per patient and 
mean cost per episode of care expressed in $A, year 2017 
values); (3) the number and costs of all episodes of care for 
3 years before and 3 years after primary LAGB bariatric 
surgery (on a year-by-year basis and totals) and calculated 
from the date of the primary surgical procedure, and the 
pre- and postoperative total costs for both LAGB and SG; 
and the relative costs of the primary surgical procedure for 
LAGB versus SG in the Tasmanian public hospital system.
Sensitivity analyses of the total inpatient costs for all surgi-
cal procedures for the study population included the investiga-
tion of cost outliers (defined as an episode of care > $A50,000). 
Subgroup analyses were conducted for patients with a reported 
history of diabetes mellitus or cardiovascular disease (inclu-
sive of hypertensive diagnosis) sourced from patient diagnoses 
tables contained within the Patient Management System. Sub-
group analyses were also conducted for patients with a BMI ≥ 
and < the median cut-point of the sample.
Surgical sequelae procedures’ key outcomes of interest 
included the inpatient episode of care’s length of stay and 
direct medical costs for surgical sequelae. Secondary surgi-
cal sequelae for the predefined study population included 
any LAGB device/implant-related procedures such as LAGB 
revisions or reversals, and LAGB port/reservoir-related pro-
cedures (e.g. port revision, port re-suturing, change of port, 
infection and/or wound or sinus debridement). Other surgi-
cal sequelae (i.e. directly related to the primary surgery) 
that generated an inpatient episode of care included hernia 
repair, cholecystectomy, complex gastrointestinal procedures 
that were LAGB related (e.g. leaks, bleeding and subsequent 
corrective surgery), any body-contouring surgery or body-
lifting procedures [38] (e.g. abdominoplasty or panniculec-
tomy) and colonoscopy and gastroscopy. Length of stay and 
cost outliers for secondary surgical sequelae were identified 
and assumed as a length of stay of > 6 days per episode of 
care and a cost of ≥ $A25,000 per episode of care.
For surgical sequelae, individual patients could be rep-
resented more than once, and this was reflected in the soci-
odemographic, clinical and cost analyses of the surgical 
sequelae and secondary procedures.
Costs were expressed in constant $A with 2016–2017 as 
the reference year (Appendix 2). There are a wide variety of 
price indexes (deflators) for the Australian health sector, and 
these may be distinguished by the scope of the index or the 
technical manner in which the indexes are constructed. Our 
study’s costs were adjusted for inflation using the price index 
for government final consumption expenditure (GFCE) on 
hospitals and nursing homes index ([39]; Appendix 2). The 
GFCE on hospitals and nursing homes index is the one that 
most appropriately reflects the scope of the health services 
being analysed in this study.
Statistical analyses were conducted with ‘R’, version 
3.0.2.
3  Results
3.1  Patient Eligibility and Characteristics
Figure 2 provides an outline of the flow of patients into the 
study. In total, 776 patients were waitlisted for ‘lap-band’ or 
‘upper gastrointestinal surgery’ on the DoH’s Patient Man-
agement System between 1 January 2008 and 31 December 
2013. Of these, 218 were removed, with 90 identified as not 
bariatric surgery (e.g. there were other gastrointestinal pro-
cedures such as bowel resection for a cancer diagnosis) and 
128 identified as secondary surgery (e.g. 43 port (reservoir) 
revisions). Therefore, 558 patients were identified as receiv-
ing primary bariatric surgery; of these, 89 received LAGB 
surgery and 16 received SG in the public hospital system. 
The number of SGs performed in the Tasmanian public 
hospital system was low over the interval, with more SGs 
performed at the end of our study’s time horizon (2014).
Detailed patient-level cost data were available for this 
study group of Tasmanian public hospital-treated patients 
but not for patients contracted to private hospitals or treated 
elsewhere.
Clinical sociodemographic characteristics of the 105 
included patients are reported in Table 2. For the LAGB 
bariatric surgery patient group, the mean ± SD age at the 
time of surgery was 47.9 ± 11.3 years and the SG bariatric 
surgery patient group was a decade older; 74% of the LAGB 
patient group and 56% of the SG patient group were female. 
The LAGB patient group’s obesity classification and comor-
bidity load revealed severe obesity (BMI 50.2 ± 10.5 kg/m2) 
with comorbidity, namely 51% (diabetes mellitus) and 53% 
(cardiovascular disease); 61% of these patients also had 
a history of smoking (previous or current smokers), and 
the recorded BMI was in the super-obesity classification 
of > 50 kg/m2. Only one BMI reading was available for the 
SG patient group. The comorbidity load for the SG patient 
group was higher, with 69% of patients reporting a history 
of diabetes mellitus and 94% a history of cardiovascular dis-
ease. Additionally, 88% of the SG patients reported a history 
of smoking. Most of the primary bariatric surgery patients 
were retired, receiving a government pension or unemployed 
(Table 2).
Of the 89 primary LAGB bariatric surgery patients, 27 
(30%) underwent surgical sequelae LAGB-related surgery. 
Compared with the primary surgical group, this patient 
group had a higher mean age at the time of surgery sequelae 
(including secondary/revisional surgery) and an increased 
prevalence of cardiovascular disease. The prevalence of dia-
betes mellitus was similar. The general trend of mean ± SD 
BMI was marginally higher: 52.2 ± 9.2 kg/m2 (Table 2). One 
of the 16 SG patients recorded a surgical sequelae event 
(outlined in section 3.2.4).
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3.2  Tasmanian Public Hospital Utilisation and Cost 
Analyses
3.2.1  Total Episodes of Care and Costs
Table 3 describes the total costs of all inpatient episodes 
of care for the study population (n = 105 patients) from the 
fiscal years 2007–2008 to 2015–2016 expressed in $A, year 
2017 values.
The total number of episodes of care for the study popula-
tion over the 8-year time horizon was 779, at a total cost to 
the Tasmanian (and to some extent Australian) healthcare 
system of $A6,018,349. This total cost included the cost 
of the primary bariatric surgery and the surgical sequelae 
(including secondary and tertiary revisional surgery).
For the entire study population (and excluding the epi-
sodes of care for the primary bariatric surgical procedures), 
the total number of inpatient episodes of care before surgery 
was 278, at a cost of $A1,589,101. After surgery (including 
the inpatient admission costs for surgical sequelae, and 
excluding the costed inpatient episodes of care for the pri-
mary bariatric surgery), the number of episodes of care was 
397, at a cost of $A2,902,043 (Table 3). The relative costs 
per episode of care for SG patients were lower than those for 
LAGB, both before and after surgery (Table 3). Addition-
ally, for the LAGB group (n = 89 patients), total costs for the 
692 episodes of care for the study population both pre- and 
postoperatively was $A5,462,275. For the SG patient group 
(n = 16 patients), total costs for the 87 episodes of care both 
pre- and postoperatively was $A556,074 (Table 3).
Regarding the total costs for the bariatric surgical proce-
dures, the total cost for primary LAGB (n = 89 patients) was 
$A1,301,367 and for surgical sequelae (including secondary 
revisional surgery) $A503,234, or an additional 39% of the 
cost of the primary procedure. The total cost for primary SG 
bariatric surgery was $A225,838 (n = 16 patients) (Table 3).
For the SG patient group (n = 16 patients), total costs 
for the 87 episodes of care both pre- and postoperatively 
Fig. 2  Flow of patients into the 
study. GI gastrointestinal
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was $A556,074. The relative costs per episode of care 
were $A7892 (LAGB) and $A6392 (SG), and the costs 
per patient were $A61,382 (LAGB) and $A34,754 (SG). 
Therefore, the total episodes of care pre- and postoperative 
costs for LAGB patients were almost twice those for SG 
patients (Table 3). One LAGB patient of the 105 patients 
recorded a catastrophic event (major gastrointestinal second-
ary surgery), with a 291-day length of stay, at a total cost of 
$A376,930. A further nine cost outliers were identified for 
the LAGB patient group, with costs ranging from $A52,749 
to $A178,253 for an episode of care (Table 3). When all cost 
outliers were omitted, total costs reduced from $A5,462,275 
to $A4,266,017 (Table 3). Sensitivity analyses also revealed 
that the relative total costs for an episode of care reduced 
by over $A1600 to $A6255 for LAGB patients and by over 
$A600 to $A5619 for SG (Table 3).
Appendices 1A and B also provide the ICD-10-CM and 
AR-DRG coding for the total episodes of care identified 
from the administrative databases for the study cohort of 
105 people who received bariatric surgery.
3.2.2  Analyses of Pre and Postoperative Public Hospital 
Utilisation and Costs
Table 4 provides analyses of all inpatient episodes of care 
and costs pre- and postoperatively for the LAGB surgical 
group (n = 89 patients) 3 years before (defined as − 3 years 
from the date of the primary procedure, − 2 years, − 1 year) 
and for the 3 years after surgery (described as + 1 year from 
the date of the primary procedure, + 2 years and + 3 years) 
as a subset of the 8-year time horizon.
Table 4 particularly highlights that the number of epi-
sodes of care and costs increased from − 3 years to − 1 year 
Table 2  Participant 
characteristics for patients who 
had primary LAGB surgery 
(n = 89) and sleeve gastrectomy 
(n = 16) surgery, and patients 
who had LAGB surgical 
sequelae (n = 27)
Data are presented as n (%) or mean ± standard deviation unless otherwise indicated
BMI body mass index, IQR interquartile range, LAGB laparoscopic adjustable gastric band, NA not applica-
ble, SD standard deviation, SG sleeve gastrectomy
a Age in years at surgery identified at the inpatient episode for the primary surgical procedure
b Age in years at surgery identified at the surgical sequelae procedure (note that the same patient may be a 
different age for a different episode)
c Available data for occupational status reflected in the n
d Available data for the occupational status reflected in the n
e n = 52
Patient characteristics (n = 105) Primary surgery Surgical sequelae
LAGB (n = 89) SG (n = 16) LAGB only (n = 27)
Number of inpatient episodes of care 89 16 58
Age years (at surgery)a
 Mean ± SD 47.9 ± 11.3 57.2 ± 8.1 51.5 ± 10.7b
 Median (IQR) 47 (40–57) 59 (50–62.3) 48.5 (44.0–60.5)
Sex
 Male 23 (26) 7 (44) 7 (26)
 Female 66 (74) 9 (56) 20 (74)
Comorbidity status
 Diabetes mellitus 45 (51) 11 (69) 12 (44)
 Cardiovascular disease 47 (53) 15 (94) 19 (70)
 Smoker (reported history) 54 (61) 14 (88) 14 (52)
Occupation  statusc
 Employed 11 (12)c 1 (6)d 3 (11)c
 Home duties 21 (24) 3 (19) 7 (26)
 Retired 17 (19) 3 (19) 6 (22)
 Pensioner 18 (20) 7 (44) 7 (26)
 Student 0 0 1 (4)
 Unemployed 5 (6) 0 1 (4)
BMI before surgery
 Mean ± SD 50.2 ± 10.5e NA 52.2 ± 9.2
 Median (IQR) 48.6 (45.8–54.1) 52.7 (48.8–58.1)
 Min; max 32.4; 97.9 32.4; 66.4
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before surgery and for the 2 years after surgery, and then 
decreased at year + 3 after surgery. More specifically, epi-
sodes of care were as follows: − 3 year, 38 episodes of 
care; − 2 year, 60 episodes of care; − 1 year, 82 episodes 
of care; + 1 year, 72 episodes of care; + 2 year, 88 episodes 
of care; + 3 year, 34 episodes of care. Costs per episode of 
care were as follows: − 3 year $A5644, − 2 year $A4881, 
− 1 year $A5508 and + 1 year $A7726; + 2 year, $A13,080 
and + 3 year $A3754. Interestingly, this result revealed that 
the number of inpatient episodes of care reduced from 82 in 
the year − 1 before surgery to 34 episodes of care year + 3 
after surgery, at an average cost of $A5508 and $A3754, 
respectively. The table also revealed that the number of epi-
sodes of care and total and average costs maximised at year 
+ 2 after surgery.
The subgroup analyses presented in Table 4 revealed that 
the general trend of a decrease of costs per episode of care 
at year + 3 after surgery was lower than for the entire study 
population. To illustrate, for patients with cardiovascular 
disease and diabetes mellitus, the difference from year − 1 
before surgery to year + 3 after surgery was $A3396 and 
$A2865, respectively, compared with $A1754 for the entire 
study population. The total cost and episodes of care max-
imised at year + 2 after surgery for the entire cohort and 
people with cardiovascular disease. Interestingly, for people 
with diabetes mellitus, average costs maximised before sur-
gery, and a decrease in average costs was revealed from the 
year + 1 after surgery (compared with year + 3 for the entire 
cohort and for people with cardiovascular disease).
3.2.3  Primary Bariatric Surgery
Table 5 describes total hospital utilisation and summary 
inpatient episode of care costs and subgroup analyses (dia-
betes mellitus and BMI) for primary LAGB and primary 
SG bariatric surgery. Figure 3a, b provide the frequency 
Table 3  Total costs of all inpatient episodes of care for patients who 
were waitlisted (1 January 2008 to 31 December 2013) and then 
underwent primary bariatric surgery in the Tasmanian public hospi-
tal system over 8 years for the fiscal years 2007–2008 to 2015–2016 
expressed in constant dollars (reference case 2016–2017 = 100), and 
sensitivity analyses (cost outliers removed)
Primary SG recorded from 2013 to 2014
LAGB laparoscopic adjustable gastric band, LoS length of stay (days), NA not applicable, SG sleeve gastrectomy 
Includes all costs (including the cost of primary bariatric surgery)
a Ten cost outliers removed for LAGB > $50,000 (namely, $52,749 primary LAGB surgery; $58,143 orthopaedic admission; $57,532 congestive 
cardiac failure admission LoS 44 days; $62,822 neurology admission LoS 7 days; $62,994 primary LAGB surgery; $95,180 multiple morbid-
ity admission LoS 16 days; $114,878 brain tumour admission LoS 42 days; $136,967 surgical sequelae from primary LAGB surgery; $178,253 
multiple morbidity LoS 43 days; and $376,930 multiple morbidity admission LoS 291 days)
b Totals before and after surgery do not include the cost of the primary surgical procedure but do include the cost of the secondary and tertiary 
surgical sequelae procedures after surgery. Note that SG = 15 for costed primary surgery
c Costs available for 15 SG only (not available for one primary bariatric surgery in 2016–17)
d One major LAGB cost outlier $376,930 included i.e. multiple morbidity admission LoS 291 days
Costs Totals Totalsa (cost outliers 
removed)
Totals before  surgeryb Totals after  surgeryb
Global (n = 105 patients)
 Episodes of care (n) 779c 768c 278b 397b
 Total costs ($) 6,018,349c,d 4,749,265 1,589,101 2,902,043
  Cost per episode 7725 6184 5716 7309
  Costs per patient 57,317 45,231 15,133 27,639
LAGB (n = 89)
 Episodes of care (n) 692 682a 219b 384b
 Total costs ($) 5,462,275c,d 4,266,017a 1,329,873 2,831,034
  Cost per episode 7892 6255 6072 7372
  Cost per patient 61,382 47,933 NA NA
 Total cost of primary surgery 1,301,367d
 Total cost of secondary surgery 503,234
SG (n = 16)
 Episodes of care (n) 87c 86a 59b 13b
 Total costs ($) 556,074c 483,249 259,228b 71,008b
  Cost per episode 6392 5619 4394 5462
  Cost per patient 34,754 30,202 16,202 4438
 Total cost of primary SG surgery (n = 15)c 225,838 NA
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Table 4  Total costs and inpatient episodes of care for patients who 
were waitlisted (1 January 2008 to 31 December 2013) and then 
underwent primary bariatric surgery in the Tasmanian public hospital 
system expressed in 2016–2017 constant dollars for the 3 years before 
and after surgery, sensitivity (cost outliers omitted) and subgroup 
analyses (patients with diabetes mellitus and cardiovascular disease)
CVD cardiovascular disease, LAGB laparoscopic adjustable gastric band, LoS length of stay
a Cost outlier > $50,000, namely $62,822 neurology
b Cost outlier > $50,000, namely $95,180 multiple medical issues not surgical sequelae
c Cost outlier > $50,000, namely $376,930 multiple issues LoS 291 days; $114,878 brain tumour LoS 42 days; $136,967 bariatric surgery cost 
outlier surgical sequelae
d Cost outliers removed
LAGB 
(n = 89)
Before surgery After surgery
− 3 years − 2 years − 1 years Total/aver-
age (before 
surgery)




38 60 82 180 72 88 34 194




5644 4881 5508 5344 (aver-
age)
7726 13,080 3754 9548 (average)
Sensitivity analyses (cost outliers removed)
 Episodes of 
care
37 60 81 178 72 85 34 191









62,822a No cost outli-
ers
95,180b 158,002 No cost outli-
ers
628,774c No cost outli-
ers
628,774
Subgroup analysis: patients with diabetes (n = 45)
 Episodes of 
care
15 19 26 60 36 49 20 105




















Subgroup analysis: Patients with CVD (n = 47)
 Episodes of 
care
23 45 55 123 56 57 23 136





6943 5426 7001 6414 8299 8671 3605 7661
 Cost outliers 
removed
1a No cost outli-
ers
1b 2 No cost outli-
ers





22 45 54 121 56 56 23 135





4491 5493 5455 5294 8299 6381 3605 6703
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distributions for inpatient LAGB episode of care costs and 
episode of care costs per day.
The mean ± SD length of stay for SG was 1.6 days longer 
than for LAGB (2.4 ± 3.6 days), but this result was not tested 
for significance. When length of stay outliers were omitted 
for LAGB sensitivity analyses (n = 6; range 6–30 days), this 
reduced to 1.7 ± 0.9 days per episode of care for primary 
LAGB bariatric surgery (Table 5).
Mean ± SD costs for an inpatient episode of care for pri-
mary LAGB and SG surgeries (that included the costs of 
the surgery) were $A14,622 ± 9142 and $A15,014 ± 5900, 
respectively. The mean costs per day for SG were half those 
for LAGB (Table 5). When cost outliers were omitted for the 
LAGB primary surgery sensitivity analyses (i.e. n = 6; range 
$A28,895–65,409), the inpatient cost per episode of care for 
primary surgery reduced to $A12,595 ± 4180. There were 
no reported cost outliers for SG primary bariatric surgery 
(Tables 3, 5; Fig. 2a). The base-case costs per day for an 
episode of care revealed that the mean ± SD costs per day 
for SG were half those for LAGB (Table 5).
Subgroup analyses for the LAGB primary surgery group 
revealed that most cost outliers were people with a reported 
history of diabetes mellitus (n = 45) (Tables 3, 5; Fig. 3c, d).
Overall, LAGB subgroup analyses for patients with or 
without diabetes mellitus revealed that the mean cost per 
inpatient episode of care for surgically treating people with 
diabetes was $A3803 higher (p = 0.02) than for people with-
out diabetes mellitus. When cost outliers were omitted from 
both samples (patients with a history of diabetes, n = 5; 
patients without a history of diabetes, n = 1), this differ-
ence reduced to only $A1725 (p = 0.07) (Table 5). Inpatient 
length-of-stay analyses revealed similar trends. Table 4 also 
revealed that the average cost per episode of care for people 
with diabetes mellitus decreased substantially from 1 year 
before surgery to 3 years after surgery and that the total cost 
was reduced by almost half.
The SG subgroup with a reported history of diabe-
tes mellitus (n = 11) revealed similar costs to those of the 
LAGB subgroup with diabetes mellitus (SG mean ± SD; 
$A15,899 ± 6491) (Table 5). Nevertheless, Table 4 showed 
that costs and episodes of care for people with diabetes mel-
litus decreased from + 1 year after surgery (compared with 
year + 3 for the entire cohort and for people with cardiovas-
cular disease).
Subgroup analyses of people with a BMI classified above 
and below the median cut-point of 48.6 kg/m2 for LAGB 
primary bariatric surgery revealed that the mean cost per 
inpatient episode of care for the primary surgical procedure 
for people with a BMI > 48.6 kg/m2 (n = 26) was $A4956 
higher than for people with a BMI ≤ 48.6 kg/m2 (n = 26). 
This result was not statistically significant. Similar trends 
were revealed for length of stay (Table 5).
3.2.4  Surgical Sequelae: Laparoscopic Adjustable Gastric 
Band and Sleeve Gastrectomy
Table 6 describes the inpatient hospital utilisation and direct 
medical costs of LAGB-related surgical sequelae and sec-
ondary LAGB surgery. The classifications of secondary/
tertiary LAGB surgery for analyses included LAGB device/
implant-related procedures (e.g. revision or reversals of the 
LAGB system, change of tubing, re-suturing of port, flipped 
port, change of port, wound or sinus debridement related 
to an infected port) and surgical sequelae of colonoscopy/
gastroscopy, hernia repair, cholecystectomy and body-con-
touring surgery.
In total, 27 patients (30%) recorded an LAGB surgical 
sequelae (including secondary/tertiary revisional surgery) 
and (n = 58) associated inpatient episodes of care. Of these 
(n = 27) patients, eight required three or more secondary 
surgical procedures and an associated inpatient episode of 
care. Over half of the surgical sequelae procedures were sec-
ondary surgery LAGB device/implant related [33 of the 58 
episodes of care (57%)], and most of these procedures were 
LAGB port/reservoir-related surgical procedures (Table 6).
A total of 16 patients required 33 episodes of care for 
LAGB device-related procedures, and 12 patients required 
27 episodes of care for LAGB port-related procedures. The 
remaining six device-related procedures were LAGB revi-
sions or reversals. Colonoscopy and gastroscopy accounted 
for ten of the 58 episodes of care of the surgical sequelae 
procedures. There were only two major LAGB-related sec-
ondary gastrointestinal surgical procedures, related to two 
patients. Only one of these procedures could be classified 
as a postoperative catastrophic event and was a major cost 
outlier of the cohort (Table 6).
The mean ± SD inpatient length of stay and costs for the 
total episodes of care for LAGB-related surgical sequelae 
were 3.5 ± 6.6 days and $A9867 ± 19,313, respectively. 
Removal of length of stay and cost outliers for sensitivity 
analyses revealed a substantial reduction in both length 
of stay and costs to 1.8 ± 1.5 days and $A6399 ± 4877 per 
inpatient episode of care (Table 6). Mean ± SD LAGB port/
reservoir-related costs per inpatient episode of care was 
$A5296 ± 3856. Revisions or reversals of the LAGB device 
(not specifically described or classified as a device/port-
related procedure) accounted for 12% of the total episodes 
of care, and the mean ± SD costs were $A11,753 ± 6423. 
Colonoscopy and gastroscopy accounted for 17% of the epi-
sodes of care, and mean ± SD costs were $A2525 ± 1104 
(Table 6). Body-contouring surgery (abdominoplasty and 
panniculectomy) was provided to one patient at a length of 
stay of 4 days (cost data not available as the procedure was 
undertaken in the current fiscal year) (Table 6).
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Of the 16 primary SG procedures, 14 were performed in 
2015 and 2016. There were 13 episodes of care recorded 
after the primary SG procedures, and one of these proce-
dures could be attributed as surgical sequelae of the primary 
SG procedure. This inpatient episode of care was a laparo-
scopic cholecystectomy performed 10 months after the SG 
procedure, at a cost of $A7759.
4  Discussion
4.1  The Costs of Obesity and Bariatric Surgery 
in Tasmania
Our study provided much-needed information regarding the 
inpatient episodes of care, resource use and costs of obe-
sity and bariatric surgery in the Tasmanian public hospital 
Table 5  Inpatient episode of care length of stay (days) and public 
hospital activity-based funding costs expressed in constant dollars 
(reference case: 2016–2017 = 100) for patients who underwent pri-
mary laparoscopic adjustable gastric band (n = 89) and sleeve gas-
trectomy (n = 16) bariatric surgery in the Tasmanian public hospital 
system, and subgroup analyses
Data are presented as mean ± standard deviation, median (interquartile range) or minimum; maximum unless otherwise indicated
BMI body mass index, LAGB laparoscopic adjustable gastric band, LoS length of stay, NA not applicable, SG sleeve gastrectomy, ToS WR test of 
significance Wilcoxon rank sum test
a Reference case 2016–2017 = 100
b Five LoS outliers removed in diabetes subgroup (range 6–30 days)
c One outlier removed in not diabetes subgroup 8 days
d Cost data for primary SG available for 15 patients (also see Table 3). Cost outliers removed > $25,000
e n = 10
*p < 0.05 level of significance
Primary surgery 
(n = 105)
Episode of care for 
primary surgery (n)
LoS LoS  
(sensitivity 
analyses)
Cost of episode  
of care
Cost of episode of care 
(sensitivity analysis)
Cost of episode of  
care per day
LAGB (n = 89)





























 ToS WR p = 0.01* p = 0.06 p = 0.02* p = 0.07

















 BMI (low) < 48.6
26 p = 0.24
1.9 ± 1.3





SG (n = 16)





NA 4030 ± 6364
3322 (3085–4583)
2186; 8040




Long-term hospital costs for bariatric surgery patients…
system. We extracted resource use and aggregated cost data 
on an individual patient basis to track the primary ABF epi-
sodes of care and the aggregated costs attributed to each 
patient pathway before and after primary bariatric surgery.
We found that total costs of public hospital inpatient 
care to the Tasmanian public healthcare system for the 105 
patients who were waitlisted for and subsequently received 
bariatric surgery in the Tasmanian public healthcare system 
over an 8-year time horizon was almost $A6.0 million, of 
which $A1.6 million was for the primary bariatric surgery 
procedures.
Another key finding was that the average cost of pro-
viding primary bariatric surgery in the Tasmanian public 
hospital system was lower than the most recent Australian 
estimate, which was derived from a sample of Queensland 
data and then extrapolated in a cost-effectiveness model. The 
base-case scenario of a severely obese 30-year-old female 
with no comorbidity was estimated to cost $A24,167 for 
a primary adjustable gastric band and $A52,440 for an 
SG [27]. We also found that our average cost of providing 
primary bariatric surgery in the Tasmanian public hospi-
tal system was lower than recent comparable international 
estimates [1].
Other findings included that cost outliers mostly involved 
patients with a reported history of cardiovascular disease and 
diabetes mellitus, and that those for LAGB surgery device/
implant-related surgical sequelae accounted for half of the 
secondary and tertiary surgery after the primary bariatric 
procedure. From a patient journey/pathway perspective, we 
also found that device-related procedures were concentrated 
to a subgroup of patients.
Fig. 3  Frequency distribution of an episode of care of inpatient costs 
expressed in constant dollars (reference 2016–2017 = 100) for all 
patients (n = 89) who received laparoscopic adjustable gastric band 
surgery (a) and cost/day for an episode of care (b). Frequency distri-
bution of inpatient episode of care costs expressed in constant dollars 
(reference 2016–2017 = 100) for all patients c with diabetes (n = 46) 
and d without diabetes (n = 45) who underwent laparoscopic adjust-
able gastric band surgery in the Tasmanian public hospital system. 
LAGB laparoscopic adjustable gastric band
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Importantly, we also found that, for people with diabetes 
mellitus, the costs for inpatient public hospital care from 
a total cost and cost per episode of care perspective were 
substantially reduced 3 years after surgery compared with 
1 year before surgery. Another interesting finding from our 
subgroup analysis was that the average cost for an episode 
of care decreased for people with diabetes mellitus from the 
first year after surgery.
A recent AIHW study estimated the cost of primary bari-
atric surgery by adopting a narrower cost base (Australian 
Medicare-linked data) than our study or the recent Austral-
ian cost–utility study [7]. The AIHW report showed that the 
costs of primary bariatric surgery were marginally lower 
than our base-case analyses. Nevertheless, this report did not 
include the broader costs captured in our study using ABF 
data linked with patient records.
Overall, our findings suggest that bariatric surgery in 
the Tasmanian public hospital system may be an attractive 
value-based proposition in the longer term: bariatric sur-
gery realised health benefits (reduced inpatient episodes of 
care) and savings (reduced costs) at year 3 postoperatively. 
At 1 year preoperatively, the study population recorded 
the highest number of inpatient episodes of care and costs, 
suggesting that the severely obese study population with 
Table 6  Length of stay and costs for surgical sequelae (including secondary/tertiary revisional surgery) after laparoscopic adjustable gastric 
band surgery, and subgroup analyses
Data are presented as mean ± standard deviation, median (interquartile range) or minimum; maximum unless otherwise indicated
LAGB laparoscopic adjustable gastric band, LoS length of stay, NA not applicable
a n = 51 costs, i.e. n = 7 costs not available
b Note that total costs for the 51 episodes of care were $503,233 (reference case: 2016–2017 = 100)
c Sensitivity analyses 1: one major cost and LoS outlier for major and complicated gastrointestinal surgery LoS 46 days (including an intensive 
care unit admission of 3199 min) and cost $136,967
d Sensitivity analyses 2: LoS outliers > 6 days (n = 6) and cost outliers ≥ $25,000 (n = 2; $136,967 and $33,119)
LAGB secondary surgery (n = 27) Episodes of care (n) Patients (n) LoS (days) Costs
Total 51 (cost)a
58 (LoS)






Sensitivity analysis  1c (cost and LoS outliers removed) 50 (cost)
57 (LoS)






Sensitivity analysis  2d (cost and LoS outliers removed) 48 (cost)
51 (LoS)



























 Colonoscopy/gastroscopy 10 9 1 day 2525 ± 1104
2285 (1729–3093)
1378; 4295
 Cholecystectomy 4 4 3 ± 1.2 9985 ± 4236c
10,610 (8041–12,241)
5470; 13,873






 Body-contouring surgery 1 1 4 NA
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multimorbidity was experiencing substantially reduced 
health 1 year before surgery. We also found that the cost of 
bariatric surgical sequelae (including secondary and tertiary 
revisional surgery) maximised at year 2. The maximisation 
of inpatient episodes of care and costs at year 2 suggests 
that postoperative care should be ongoing during this critical 
time horizon and could potentially mitigate some of these 
inpatient costs.
4.2  Surgical Sequelae (Including Secondary/
Tertiary Surgery)
Our investigation of patient-level data regarding surgical 
sequelae after primary LAGB surgery is novel. We tracked 
each publicly treated LAGB and SG patient’s individual 
inpatient episode of care and cost pathway to provide our 
project partners with a comprehensive understanding of the 
patient pathway, the prevalence of surgical sequelae and sec-
ondary and tertiary surgery resource use and costs.
Importantly, our study found that over half of the costs of 
complications and reoperations for publicly treated LAGB 
patients were device related and that these episodes of care 
and costs were mostly LAGB port/reservoir related and con-
centrated to a further subgroup of patients. Nevertheless, 
the overall costs of bariatric surgery (including the total 
costs of reoperations and complications) for our older and 
sicker cohort of bariatric surgery patients were less than the 
direct medical costs reported in the most recent Australian 
cost–utility study.
We also found that, for SG, one in 16 inpatient episodes 
of care could be attributed to surgical sequelae. However, 
the time horizon for this small sample of patients who had 
received an SG was also short.
A recent comprehensive systematic review regarding 
the health economic evaluation of bariatric surgery found 
that one-third of the 77 included studies either ignored the 
costs and/or consequences of complications and reopera-
tions or, for the studies that accounted for reoperations and 
complications, commonly only assumed short-term events, 
considered an incomplete list of complications or assumed 
relatively low probabilities of adverse events occurring. The 
review also found that the longer-term costs of bariatric sur-
gery have therefore probably been underestimated and the 
value for money of bariatric surgery subsequently overesti-
mated. Additionally, the most recent Australian cost–util-
ity study estimated the prevalence of surgical sequelae and 
secondary surgery from the literature (notwithstanding esti-
mating the surgical costs from an administrative database).
In direct comparison, our study suggests that the most 
recent health economics studies have underestimated the 
prevalence and real costs of surgical sequelae and second-
ary/tertiary bariatric surgery.
4.3  Resource Allocation: Type of Surgery 
and Patient Prioritisation
Contemporary debate regarding the provision of bariatric 
surgery has, to a certain degree, shifted beyond the cost per 
quality-adjusted life-year health economic metric to the eco-
nomic barriers to entry in public healthcare systems and 
the associated issue of supply not meeting ever-increasing 
demand for publicly provided bariatric surgery [24, 40].
Other authors have called for a reconsideration of the use 
and role of adjustable gastric band surgery (compared with 
other procedures such as SG), particularly for Medicare ben-
eficiaries in the USA [14–16]. A recent key epidemiological 
study that investigated reoperations and Medicare (USA) 
expenditures after LAGB surgery found that device-related 
reoperation was common and costly and varied widely 
across hospital referral regions [41]. On the other hand, 
it has been suggested that no single bariatric procedure is 
appropriate for all patients and that the regional variation in 
outcomes observed is important [15].
Given our study’s reported rates (and costs) of secondary/
tertiary LAGB device-related surgery, policy makers could 
reconsider the type of surgery provided to certain patient 
groups to mitigate LAGB device-related issues.
A common theme that emerged from a review of the 
health economics reporting of bariatric surgery was that it 
is highly cost effective (and even cost saving) for severely 
obese patients with type 2 diabetes mellitus [1]. Our sub-
group analyses revealed that half of our severely obese 
cohort had a history of diabetes mellitus and that the cost 
of providing them with the primary surgical procedure was 
only marginally higher than that for people without diabe-
tes mellitus. More importantly, our subgroup analyses for 
people with diabetes mellitus also found that total costs of 
publicly funded inpatient care were substantially reduced 
3 years after bariatric surgery.
Our previously published work also found that long-wait-
ing public hospital system bariatric surgery patients should 
not be ‘written-off’ by healthcare planners—they can still 
realise significant improvements in health-related quality-
of-life outcomes when ultimately treated, and this should be 
factored into patient prioritisation decisions [42]. Our pre-
viously published work also suggested that addressing this 
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issue given the large gap between the demand for and sup-
ply of publicly funded bariatric surgery in many countries, 
would require significant commitment and investment [42].
4.4  Strategic Research Alliance in an Applied Health 
Economics Study
Our study harnessed the comparative advantages of a strate-
gic alliance between university researchers and government 
policy makers that comprised heterogeneous human capital. 
The team identified key gaps for the state government part-
ner regarding the resource use and costs of publicly provided 
bariatric surgery, including a comparison between LAGB 
and SG surgery. Additionally, this study has enabled uni-
versity researchers to build on a collaborative relationship 
with our health partner.
4.5  Limitations and Strengths
The main limitation of our study was the small sample size 
and shortened time horizon for SG and the single-centre 
nature of our study (the Tasmanian hospital system), there-
fore limiting the overall generalisability of the study. Nev-
ertheless, our Tasmanian State Government partner indi-
cated that this study and the investigation of the small yet 
pragmatic sample of SG patients was important and that we 
should track each patient journey for both LAGB and SG. 
We recommend that a larger confirmatory study of disag-
gregated costs for later years be conducted given that SG as 
a treatment option in the Tasmanian public hospital system 
from 2014 may have increased.
A further limitation was that our study focused on the 
inpatient hospitalisation and direct medical costs (com-
pared with, for example, primary care). On the other hand, 
this focus was also a key strength of our paper because 
we provided our policy decision makers with important 
information about the study population that was previously 
unknown. Two further strengths were the overall sample 
size of bariatric surgery patients and their associated before 
and after surgery episodes of care individually tracked for 
a long time horizon and that we collected sufficient data 
to enable sensitivity and subgroup analyses over a long 
timeframe.
A final limitation concerns our assumption that secondary 
surgical sequelae included colonoscopies. However, only a 
few colonoscopies were identified in the sample (combined 
gastroscopy and colonoscopy, ten episodes of care), and a 
proportion of this small sample would be directly related to 
LAGB surgery. We suggest that a larger confirmatory study 
also investigate the rate of colonoscopy and gastroscopy for 
the Tasmanian public hospital system.
5  Conclusions
The costs of providing bariatric surgery in Tasmania are 
lower than comparable national and international published 
estimates, even after Tasmanian costs for surgical sequelae 
and secondary/tertiary surgery are included. A robust cost-
effectiveness study could be the subject of further research 
for the retrospective cohort and our planned prospective 
cohort.
Targeting appropriately prioritised patients with SG in 
preference to LAGB surgery in Tasmania could mitigate 
LAGB implant-related costs.
Patients with diabetes mellitus and cardiovascular disease 
incur lower costs in the longer term after bariatric surgery.
This study and our health-related quality-of-life work 
provide the building blocks for our project team to conduct 
a robust real-world cost-effectiveness analysis for our DoH 
project partner. We also recommend that a larger confirma-
tory cost study be conducted to investigate disaggregated 
ABF costs about SG versus LAGB (and other forms of bari-
atric surgery that could now be offered) in the Tasmanian 
public hospital system from 2013–2014 to 2018–2019.
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Appendix 1A
The principal and additional diagnoses for all International 
Classification of Diseases—Tenth Edition—Clinical Modi-
fications (ICD-10-CM) codes for people who received pri-
mary and surgical sequelae (including secondary and ter-
tiary) laparoscopic adjustable gastric band surgery in the 
Tasmanian public hospital system.







E66.9 Obesity not elsewhere classified
E10.61 Type 1 diabetes mellitus with 
specified diabetic musculo-
skeletal and connective tissue 
complication
E10.64 Type 1 diabetes mellitus with 
hypoglycaemia
E11.21 Type 2 diabetes mellitus with 
incipient diabetic nephropathy
E11.22 Type 2 diabetes mellitus with 
established diabetic nephropathy
E11.31 Type 2 diabetes mellitus with 
background retinopathy
E11.4 Type 2 diabetes mellitus with 
neurological complication
Principal and secondary diagno-
sis ICD-10-CM codes
Description
E11.65 Type 2 diabetes mellitus with poor 
control
E11.71 Type 2 diabetes mellitus with 
multiple microvascular and 
other specified nonvascular 
complications
E11.72 Type 2 diabetes mellitus with 
features of insulin resistance
E87.6 Hypokalaemia
G47.32 Obstructive sleep apnoea syn-
drome
G62.9 Polyneuropathy, unspecified
H35.0 Background retinopathy and 
retinal vascular changes
I10.0 Essentially (primary) hyperten-
sion
I20.0 Incisional hernia without obstruc-
tion or gangrene
I95.5 Hypotension
I97.8 Other intraoperative and post 
procedural complications and 
disorders
I99.59 Chronic embolism and thrombosis 
of other specified deep vein of 
lower extremity
K31.88 Other specified diseases of stom-
ach and duodenum
K42.9 Umbilical hernia without obstruc-
tion or gangrene
K43.2 Incisional hernia without obstruc-
tion or gangrene
K43.9 Other unspecified ventral hernia 
without obstruction or gangrene
K44.9 Diaphragmatic hernia without 
obstruction or gangrene
K55.8 Other vascular disorders of 
intestine
K56.5 Intestinal adhesions [bands] with 
obstruction
K66.0 Peritoneal adhesions
K80.1 Calculus of gallbladder with other 
cholycystitis
K92.2 Gastrointestinal haemorrhage, 
unspecified
M79.58 Residual foreign body in soft tis-
sue, other site
M79.61 Achilles tendonitis, right leg
M79.62 Pain in limb shoulder region
N18.2 Chronic kidney disease stage 2
N18.9 Chronic kidney disease unspeci-
fied
N99.0 Post procedural kidney failure.
R00.0 Tachycardia, unspecified
R00.1 Bradycardia unspecified
R07.4 Chest pain, unspecified
 J. A. Campbell et al.
Principal and secondary diagno-
sis ICD-10-CM codes
Description
R10.4 Other unspecified abdominal pain
R19.5 Other faecal abnormalities
R51 Headache
R52 Headache
S35.2 Injury of celiac or mesenteric 
artery and branches
S36.52 Injury of transverse colon
T43.0 Tricyclic and tetracyclic antide-
pressants
T81.0 Haemorrhage or haematoma 
complicating a procedure, not 
elsewhere classified
T81.1 Post procedural shock
T81.2 Post-procedural shock
T81.4 Infection following a procedure
T81.2 Accidental puncture and lac-
eration during a procedure, not 
elsewhere classified
T85.6 Mechanical complication of inter-
nal prosthetic devices implants 
and grafts not elsewhere clas-
sified
T85.78 Infection and inflammatory reac-
tion to other internal prosthetic 
devices, implants and grafts
U79.3 Depression
U82.3 Hypertension
U86.2 Arthritis and osteoarthritis
Y60.0 Unintentional cut, puncture, perfo-
ration or haemorrhage during 
surgical operation
Y60.8 Unintentional cut, puncture, perfo-
ration or haemorrhageduring 
other surgical and medical care
Y83.1 Surgical operation with implant of 
artificial internal device
Y92.22 Place of occurrence health service 
area
Z41.1 Other plastic surgery for unaccep-
table cosmetic appearance
Z72.0 Tobacco use current
Z80.0 Family history of malignant neo-
plasm of digestive organs
Z86.43 Personal history of tobacco use 
disorder
Z92.21 Personal history of long-term 
(current) use of medicaments 
aspirin
Z92.22 Personal history of monoclonal 
drug therapy
Z95.5 Presence of coronary angioplasty 
and graft
Z96.8 Presence of other specified func-
tional implants
Appendix 1B
Australian Refined Diagnostic Related Groups for people 
who received primary laparoscopic adjustable gastric band 
primary and surgical sequelae in the Tasmanian public hos-
pital system.
AR-DRG Description
F21B Other circulatory system general interventions, intermedi-
ate complexity
G02A Major small and large bowel procedures, major complex-
ity
G02B Major small and large bowel procedures, intermediate 
complexity
G04C Peritoneal adhesiolysis, minor complexity
G05C Minor small and large bowel procedures
G10B Hernia procedures, minor complexity
G11Z Anal and stomal procedures
G47C Gastroscopy, minor complexity
G48A Colonoscopy, major complexity
G48B Colonoscopy, minor complexity
G48C Colonoscopy, same day
H07A Open cholecystectomy, major complexity
H08A Laparoscopic cholecystectomy, major complexity
H06B Other hepatobiliary and pancreas general interventions, 
intermediate complexity
H08B Laparoscopic cholecystectomy, minor complexity
K04A Major procedures for obesity
K04B Major procedures for obesity
K04Z Major procedures for obesity
K10A Revisional and open bariatric procedures, major complex-
ity
K12Z Other bariatric procedures
T01C Infectious and parasitic diseases with general interven-
tions, minor complexity
X06B Other procedures for other injuries, intermediate complex-
ity
X63B Sequelae of treatment, minor complexity
Z01B Other contacts with health services with GIs, minor 
complexity
Z40Z Other contacts with health services with endoscopy
Source: Independent Hospital Pricing Authority, Australian Refined 
Diagnosis Related Groups Version (6.0-9.0)
Appendix 2
Health indices—general final consumption expenditure 
(GFCE) on hospitals and nursing homes (reference year 
2016–2017 = 100).



























77.7 80.1 82.6 85.7 86.9 89.0 91.6 94.1 96.4 98.2 100.0
Sourced from Australian Institute of Health and Welfare Health Expenditure Australia Report 2016–2017
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